Close Menu

Wellcome Sanger Institute

Some population-specific structural variation was shared with archaic human groups, suggesting they arose through long-ago introgression.

Independent research teams have tackled the genetic history of the Levant, Anatolia, and other parts of the Near East to retrace population movement and mixing since the Bronze Age.

In Nature this week: method to cluster cells based on single-cell RNA sequencing reads, synthetic genomics platform reconstructs SARS-CoV-2, and more.

Research institutions in the US and Europe will lead the studies, which will explore different aspects of COVID-19 such as host immune response.

These cells in the nose may serve as the virus entry point, according to an analysis of a single-cell RNA sequencing dataset spanning multiple tissue types.

The sequencing-based analysis also found that some of these cancer-linked alterations in endometrial glands may occur early in life.

A nationwide, multi-agency effort to sequence the virus causing COVID-19 is a logistical nightmare, but experts say the UK is well situated to succeed.

Following its Path

The UK is launching a research consortium to sequence SARS-CoV-2 samples from patients.

The consortium, which spans more than a dozen UK cities, will sequence patient samples to understand the spread and evolution of the novel coronavirus.

In Science this week: sequencing of diverse human genomes gives insight into genetic variation and population history, commentary on data sharing, and more.

Pages

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.